




# Advanced Bifurcation Systems

Advanced Bifurcation Systems (ABS) is a clinical stage medical device company developing an innovative stenting platform for the treatment of bifurcation lesions in coronary angioplasties. ABS has developed a bifurcating stent which overcomes the limitations of current approaches.


## Technology

- Proprietary bifurcation drug-eluting stenting system
- Mother/Daughter (MD) platform technology for treatment of ALL CAD bifurcation cases
- Only stenting solution capable of complete coverage regardless of branch angles, sizes, and plaque locations
- First-in-Human trials with successful 12-month follow up


## Mother/Daughter (MD) Platform



Tracking of mother and daughter catheters over both guidewires. The daughter catheter is pulled back in position.




The daughter catheter balloon is inflated, deploying the daughter stent simultaneously with proximal segment of the main branch stent.



Inflation of the mother catheter balloon, deploying the mother stent. Procedure is finalized using simultaneous final kissing balloon inflation.

ABS's patented technology lies both in the design of the main and side branch stents and the methodology of assembling an independently, moveable, modular bifurcating stenting system at the carina or fixed point of a bifurcation. The Company's groundbreaking system consists of numerous differentiating features, including a unique dual-catheter setup and deployment as well as a proprietary crimping technology allowing for partial crimping of the main stent. The main stent opening and corresponding side stent alignment is automatic and obviates the need for the torquing and micro alignment required in other techniques. Furthermore, the installation leaves no gaps or excess metal overlaps.


## First Human Trial



- Complete coverage for all lesions
  - Branch angles, size, plaque burden and location
- Single system addresses main and side branch
- Self alignment and perfect placement
- Mechanically fail-safe
  - Automatic main vessel aperture and side vessel alignment
- No torquing or micro alignment
  - No gaps and/or overlaps
- Significantly reduces risk of restenosis and thrombosis



## Advanced Bifurcations Systems - Estimated Timeline



*The company is currently capital efficient, with only \$5 million invested.*

### Market Need - Percutaneous Coronary Intervention (PCI)

- Current coronary artery stents are either bare metal stents (BMS) or drug-eluting stents (DES)
  - Average restenosis rate with stents is about 2% with DES, compared to 18% for BMS
  - DES requires longer period of dual anti-platelet (blood thinners) therapy
- Coronary stent global market approximately \$10 billion in 2016
  - Estimated to reach \$15 billion by 2024
- 25-30% of all coronary disease involves bifurcations
- Restenosis and target vessel revascularization rates at bifurcations are significantly higher

### Investment Opportunity

- **Cardiologist Developed Stent Technology**
  - Intuitive and effective solution for an unmet clinical need
- **Only Solutions to Simplify Procedure, Reduce Risk/Cost, and Improve Outcomes**
- **Bifurcation Stenting ≈ \$2B Market Opportunity**
  - Bifurcation stenting targets large subset of ~\$10.5B annual global coronary stent market
- **Strong Early Human Trial Data**
- **Extensive IP protection**
  - To date 33 patents issued/granted
- **Experienced Management Team and Stellar Advisory Board**
  - Extensive experience with coronary stenting practice, R&D, start-up and commercialization of medical technology

### Exceptional Management Team

#### Charles A. Laverty

Chief Executive officer

*> 30 years career in capital markets and senior management positions including Chairman & CEO of multiple medical device companies*

*U.S. Turnaround entrepreneur of year as Chairman & CEO of Curaflex Health Services –Morgan Stanley private investment company, Granted by Merrill Lynch & Ernst &Young (EY)*

#### Mehran J. Khorsandi, MD

Co-Founder, Chairman & Chief Medical Officer  
*Interventional cardiologist at Cedars-Sinai Medical Center, Member of the team that developed the HARTS stent at Cedars-Sinai*

*Co-inventor of ABS stent technology with multiple U.S. patents pending*

#### Henry Bourang

Co-Founder, President & CTO

*> 29 years senior Management and technical experience in medical device industry*

*More than 100 U.S. and international issued and pending patents*

### Contact

#### Advanced Bifurcations Systems

Charles Laverty  
charles\_laverty@advancedbifurcation.com  
+1 925 989 2027  
1451 Quail Street, Suite 104  
Newport Beach CA 92660

#### MBS Value Partners

Lisa Sher/Betsy Brod  
lisa.sher@mbsvalue.com  
betsy.brod@mbsvalue.com  
+1 212 750 5800